Uroplasty said that the reimbursement rates for the procedure have not yet been established, the new CPT code number has not been assigned, and reimbursement requests using the new CPT code may not be submitted prior to January 2011.

Further, the code will not ensure that additional reimbursement agencies beyond those that currently cover the procedure, whether governmental agencies or private payers, will cover PTNS treatments.

Minnesota-based Uroplasty is a medical device company that develops, manufactures and markets proprietary products to treat voiding dysfunctions.

It’s primary focus is the continued commercialisation of Urgent PC System, which is the FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence symptoms often associated with overactive bladder.

Uroplasty also offers Macroplastique, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.